Drug Trial Radar · NCT04603495
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
430
Actual
Start
Apr 9, 2021
Primary completion
Aug 23, 2023
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Conditions
- Myelofibrosis
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
Interventions
PelabresibDrug
Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days). Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.
RuxolitinibDrug
Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
PlaceboDrug
Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Splenic Response by Central Radiology Reads at Week 24Time frame: Week 24
Locations
156 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
Chandler, Arizona
UC San Diego Moores Cancer Center
La Jolla, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Medical Center
Los Angeles, California
Yale University School of Medicine
New Haven, Connecticut
Mayo Clinic
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL
Decatur, Illinois
Franciscan Health/Indiana blood and Marrow Transplantation
Indianapolis, Indiana
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky
University of Michigan Medical Center
Ann Arbor, Michigan
Washington University
St Louis, Missouri
Icahn School of Medicine at Mount Sinai
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Medical College- New York Presbyterian Hospital
New York, New York
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
MD Anderson Cancer Center
Houston, Texas
University of Texas Health Science Center - San Antonio
San Antonio, Texas
Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute
Seattle, Washington
USC Clinical Trials Centre Sunshine Coast Haematology and Oncology Clinic
Buderim, Australia
One Clinical Research PTY LTD
Nedlands, Australia
Icon Cancer Centre
Brisbane, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Monash Health
Clayton, Victoria, Australia
Peninsula Private Hospital Clinical Trials Unit
Frankston, Victoria, Australia
LKH - Universitätsklinikum Graz; Abteilung für Hämatologie
Graz, Austria
Krankenhaus der Elisabethinen Linz
Linz, Austria
Kepler University Hospital
Linz, Austria
University Hospital Salzburg
Salzburg, Austria
ZNA
Antwerp, Belgium
Cliniques universitaires Saint-Luc
Brussels, Belgium
Hôpital de Jolimont
La Louvière, Belgium
UZ Leuven
Leuven, Belgium
Domaine Universitaire du Sart Tilman
Liège, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
London Health Sciences Center - Victoria Hospital
London, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Showing 40 of 156 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.